The cost effectiveness of peginterferon alfa and ribavirin for the treatment of hepatitis C in children and young people
The cost effectiveness of peginterferon alfa and ribavirin for the treatment of hepatitis C in children and young people
OBJECTIVES: To assess the cost-effectiveness of peginterferon ?-2a and peginterferon ?-2b in combination with ribavirin compared to best supportive care (BSC), for the treatment of chronic hepatitis C virus (HCV) in children and young people aged 3 to 17 years.
METHODS: A Markov state-transition economic model of chronic HCV in children and young people was developed that extrapolated the impact of sustained virological response (SVR) on life expectancy, quality-adjusted life expectancy and lifetime costs. The model was adapted from one previously developed for adults. A systematic review was conducted of the clinical effectiveness of the treatments, and the health related quality of life for patients with hepatitis C. Uncertainty was explored through probabilistic and deterministic sensitivity analyses.
RESULTS: Seven studies were identified that were relatively small and of generally poor quality. Estimates of SVR were similar for for peginterferon ?-2a (60%) and peginterferon ?-2b (58%) was similar, whilst the SVR for no treatment was assumed to be zero. From this model, peginterferon alfa (?-2a or ?-2b) in combination with ribavirin was more effective and cheaper than BSC. Sensitivity analyses suggest that the results were generally robust to all changes to the structural assumptions and input parameters. The model results were most sensitive to changes to the discount rate, time horizon, SVR and baseline fibrosis of the cohort.
CONCLUSIONS: Treatment of children and young people with peginterferon alfa (?-2a or ?-2b) and ribavirin may be an effective therapy. Peginterferon alfa (?-2a or ?-2b) in combination with ribavirin is cost-effective compared with BSC. However, the available evidence is of poor quality. The views expressed in this paper are those of the authors and do not necessarily represent the views or policies of the UK HTA programme or Department of Health.
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Baxter, L.
eeafbfe7-ae7e-421f-a6b6-c6d9df80b6ef
Loveman, Emma
06ff1bf1-0189-4330-b22d-f5a917e9871d
Hartwell, Debbie
e6a0eaa0-956d-45fb-9b7d-03ca1af3334c
Frampton, G.K.
1976227d-3ecc-459e-bfba-ca85e61dfc0f
3 November 2013
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Baxter, L.
eeafbfe7-ae7e-421f-a6b6-c6d9df80b6ef
Loveman, Emma
06ff1bf1-0189-4330-b22d-f5a917e9871d
Hartwell, Debbie
e6a0eaa0-956d-45fb-9b7d-03ca1af3334c
Frampton, G.K.
1976227d-3ecc-459e-bfba-ca85e61dfc0f
Cooper, Keith, Baxter, L., Loveman, Emma, Hartwell, Debbie and Frampton, G.K.
(2013)
The cost effectiveness of peginterferon alfa and ribavirin for the treatment of hepatitis C in children and young people.
ISPOR 16th Annual European Congress, Dublin, Ireland.
02 - 06 Nov 2013.
Record type:
Conference or Workshop Item
(Poster)
Abstract
OBJECTIVES: To assess the cost-effectiveness of peginterferon ?-2a and peginterferon ?-2b in combination with ribavirin compared to best supportive care (BSC), for the treatment of chronic hepatitis C virus (HCV) in children and young people aged 3 to 17 years.
METHODS: A Markov state-transition economic model of chronic HCV in children and young people was developed that extrapolated the impact of sustained virological response (SVR) on life expectancy, quality-adjusted life expectancy and lifetime costs. The model was adapted from one previously developed for adults. A systematic review was conducted of the clinical effectiveness of the treatments, and the health related quality of life for patients with hepatitis C. Uncertainty was explored through probabilistic and deterministic sensitivity analyses.
RESULTS: Seven studies were identified that were relatively small and of generally poor quality. Estimates of SVR were similar for for peginterferon ?-2a (60%) and peginterferon ?-2b (58%) was similar, whilst the SVR for no treatment was assumed to be zero. From this model, peginterferon alfa (?-2a or ?-2b) in combination with ribavirin was more effective and cheaper than BSC. Sensitivity analyses suggest that the results were generally robust to all changes to the structural assumptions and input parameters. The model results were most sensitive to changes to the discount rate, time horizon, SVR and baseline fibrosis of the cohort.
CONCLUSIONS: Treatment of children and young people with peginterferon alfa (?-2a or ?-2b) and ribavirin may be an effective therapy. Peginterferon alfa (?-2a or ?-2b) in combination with ribavirin is cost-effective compared with BSC. However, the available evidence is of poor quality. The views expressed in this paper are those of the authors and do not necessarily represent the views or policies of the UK HTA programme or Department of Health.
Text
ISPOR Hep C1.pdf
- Other
More information
Published date: 3 November 2013
Venue - Dates:
ISPOR 16th Annual European Congress, Dublin, Ireland, 2013-11-02 - 2013-11-06
Organisations:
Faculty of Business, Law and Art
Identifiers
Local EPrints ID: 359786
URI: http://eprints.soton.ac.uk/id/eprint/359786
PURE UUID: 7fb16a3c-6d78-449f-a3ac-825531b150cd
Catalogue record
Date deposited: 12 Nov 2013 14:36
Last modified: 15 Mar 2024 03:05
Export record
Contributors
Author:
L. Baxter
Author:
Debbie Hartwell
Author:
G.K. Frampton
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
